Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286194 · ClinicalTrials.gov registry record
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
A clinical trial, sponsored by Eisai.
- Completed
- Registry status
- 1,500
- Enrollment target
NCT01286194: Completed study, sponsored by Eisai.
NCT01286194 is a clinical trial that has completed, run by Eisai. The registered enrollment target is 1,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01286194 has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- 1,500 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
Interventions
- DRUG Rabeprazole sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-01 |
What the finished NCT01286194 record still lists
NCT01286194 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Rabeprazole sodium is the first listed.
NCT01286194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01286194 about?
NCT01286194 is a clinical study titled "A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms". This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
What is the current status of trial NCT01286194?
This trial is currently completed. The enrollment target is 1,500 participants. The study started on 2006-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT01286194?
The interventions under investigation include: Rabeprazole sodium (DRUG).
Who is sponsoring clinical trial NCT01286194?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia